GenoImmune, a BGI Company, Completes Funding for NeoAntigen Cell Therapies
publication date: Aug 15, 2022
GenoImmune Therapeutics, a Wuhan company founded by China’s gene sequencing company, BGI, closed a funding round to support its immuno-cell therapy products. The company’s core technologies include its AI-driven neoantigen technology, a GMP cell preparation platform and mRNA tumor vaccines aimed at solid tumors including melanoma, lung cancer and colorectal cancer. Using its AI-based screening, GenoImmune can identify novel tumor antigens that are used in T-Cell and Neo-T cell therapies. In previous $15+ million rounds, the company attracted Hillhouse, ForeBright and Wuhan East-lake Venture Capital as investors. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.